Preview

Колопроктология

Расширенный поиск

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ РОССИЙСКОЙ ГАСТРОЭНТЕРОЛОГИЧЕСКОЙ АССОЦИАЦИИ И АССОЦИАЦИИ КОЛОПРОКТОЛОГОВ РОССИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЯЗВЕННОГО КОЛИТА

Полный текст:

Об авторах

В. Т. Ивашкин

Россия


Ю. А. Шелыгин

Россия


И. Л. Халиф

Россия


Е. А. Белоусова

Россия


О. С. Шифрин

Россия


Д. И. Абдулганиева

Россия


Р. А. Абдулхаков

Россия


О. П. Алексеева

Россия


С. А. Алексеенко

Россия


С. И. Ачкасов

Россия


А. Ю. Барановский

Россия


К. В. Болихов

Россия


Е. Ю. Валуйских

Россия


А. В. Варданян

Россия


А. В. Веселов

Россия


В. В. Веселов

Россия


А. О. Головенко

Россия


О. В. Головенко

Россия


Е. Г. Григорьев

Россия


И. В. Губонина

Россия


Т. Н. Жигалова

Россия


В. Н. Кашников

Россия


Е. А. Кизова

Россия


О. В. Князев

Россия


Н. В. Костенко

Россия


А. В. Куляпин

Россия


Н. А. Морозова

Россия


А. В. Муравьев

Россия


А. А. Низов

Россия


Н. В. Никитина

Россия


Н. Н. Николаева

Россия


Н. В. Никулина

Россия


А. Х. Одинцова

Россия


М. Ф. Осипенко

Россия


В. В. Павленко

Россия


А. И. Парфенов

Россия


Е. А. Полуэктова

Россия


А. С. Потапов

Россия


В. Г. Румянцев

Россия


И. О. Светлова

Россия


С. И. Ситкин

Россия


В. М. Тимербулатов

Россия


А. В. Ткачев

Россия


Е. И. Ткаченко

Россия


С. А. Фролов

Россия


Д. А. Хубезов

Россия


Е. Ю. Чашкова

Россия


М. В. Шапина

Россия


О. Б. Щукина

Россия


А. А. Яковлев

Россия


Список литературы

1. Travis S.P., Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract. Gastroenterol. - 2010; 30: 17-20.

2. D’Haens G. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. -2007; 132: 763-86.

3. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. - 2011; 140: 1785-94.

4. Katsanos K.H., Vermeire S., Christodoulou D.K., Riis L., Wolters F., Odes S. et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion. - 2007; 75: 113-21.

5. Silverberg M.S. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. - 2005; 19 (Suppl A): 5-36.

6. Truelove S.C. et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. - 1955; 2: 1041-8.

7. Seah D., De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment. Pharmacol.Ther. - 2016 Feb;43 (4):482-513.

8. Hindryckx P., Jairath V., D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat. Rev. Gastroenterol. Hepatol. - 2016 Sep 1.

9. Chen J.H., Andrews J.M., Kariyawasam V., Moran N. IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis -evidence-based consensus statements. Aliment. Pharmacol.Ther. - 2016 Jul; 44 (2): 127-44.

10. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. - 1987; 317: 1625-9.

11. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. - 2011. - № 15. -с. 44-49

12. Issa M., Vikayapal A., Gracham M.B. et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin.Gastroenterol.Hepatol. - 2007; 5: 345-351.

13. Rodeman J.F., Dubberke E.R., Reske K.A. et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin.Gastroenterol.Hepatol. - 2007; 5: 339-344.

14. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. - 2008; 14: 1432-42.

15. Nguyen G.C., Kaplan G.G., Harris M.L. et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. - 2008; 103: 1443-50.

16. Mindenmark M., Larsson A. Rulling out IBD estimation of the possible economic effects of preendoscopic screening with F-calprotectin. Clin. Biochem. - 2012; 45: 552-5.

17. Costa F., Mumolo M.G., Bellini M., Romano M.R., Ceccarelli L., Arpe P. et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver. Dis. - 2003; 35: 642-7.

18. Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. - т. 17. - №3. - с. 65-71.

19. Ивашкин В.Т., Шептулин А.А., Шифрин О. С., Галимова С.Ф., Юрманова Е.Н. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2006. - т. 16. - №6. -с. 56-60.

20. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. - 2013. - №2. - с. 42-46.

21. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2006. - т. 16. -№3. - с. 58-62.

22. Dignass A. et al. Second EUROPEAN evidence based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn’s and Colitis. - 2012.

23. Халиф И.Л. Принципы лечения язвенного колита (Рекомендации российской группы по изучению воспалительных заболеваний кишечника). Колопроктология. - 2006. №2. - с. 31-33.

24. Su C., Lewis J.D., Goldberg B., Brensinger C., Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. - 2007; 132: 516-26.

25. Marshall J.K., Thabane M., Steinhart A.H., Newman J.R., Anand A., Irvine E.J. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. -2010 [CD004115-CD004115].

26. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. - 1997; 40: 775-81.

27. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig. Dis. Sci. - 2011; 56: 513-22.

28. Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. - 1997; 92: 1867-71.

29. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. -2006:CD000543.

30. Regueiro M., Loftus Jr E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm. Bowel Dis. -2006; 12: 979-94.

31. Ford A.C., Achkar J-P., Khan K.J., Kane S.V., Talley N.J., Marshall J.K. et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol. -2011; 106: 601-16.

32. Kane S.V., Bjorkman D.J. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev. Gastroenterol.Disord. - 2003; 3: 210-8.

33. Ford A.C., Achkar J-P., Khan K.J., Kane S.V., Talley N.J., Marshall J.K. et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol. -2011; 106: 601-16.

34. Kane S.V., Bjorkman D.J. The efficacy of oral 5-ASAs in the reatment of active ulcerative colitis: a systematic review. Rev. Gastroenterol.Disord. - 2003; 3: 210-8.

35. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. -2006:CD000543.

36. Lichtenstein G.R. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig. Dis. Sci. - 2016 Feb; 61 (2): 358-70.

37. Sherlock M.E., MacDonald J.K., Griffiths A.M., Steinhart A.H., Seow C.H. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. - 2015 Oct 26;(10):CD007698.

38. Danese S., Siegel C.A., Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol.Ther. - 2014 May; 39 (10): 1095-103.

39. Gisbert J.P., Linares P.M., McNicholl A.G., Mate J., Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment. Pharmacol.Ther. - 2009; 30: 126-37.

40. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. - 2010; 362 (15): 1383-95.

41. Yarur A.J., Rubin D.T. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm. Bowel Dis. - 2015 Jul; 21 (7): 1709-18.

42. Steenholdt C., Bendtzen K., Brynskov J., Ainsworth M.A. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm. Bowel Dis. - 2016 Aug; 22 (8): 1999-2015.

43. Panaccione R., Ghosh S., Middleton S. et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J. Crohns Colitis. - 2011; 5: 13.

44. Gonzalez-Huix F., Fernandez-Banares F., Esteve-Comas M., Abad-Lacruz A., Cabre E., Acero D. et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am. J. Gastroenterol. -1993; 88: 227-32.

45. Khan K.J., Ullman T.A., Ford A.C., Abreu M.T., Abadir A., Abadir A. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. - 2011; 106: 661-73.

46. Ohkusa T., Kato K., Terao S., Chiba T., Mabe K., Murakami K. et al. Newly developed antibiotic combination therapy for ulcerative colitis: a doubleblind placebo-controlled multicenter trial. Am. J. Gastroenterol. - 2010; 105: 1820-9.

47. Gionchetti P., Rizzello F., Ferrieri A., Venturi A., Brignola C., Ferretti M., Peruzzo S., Miglioli M., Campieri M. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroidtreatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. - 1999 Jun; 44 (6): 1220-1.

48. Frey B.M., Frey F.J. Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. -1990 Aug; 19 (2): 126-46.

49. Turner D. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin.Gastroenterol.Hepatol. - 2007 Jan; 5 (1): 103-10.

50. Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. - 2005; 128: 1805-11.

51. Lees C.W., Heys D., Ho G.T., Noble C.L., Shand A.G., Mowat C. et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. - 2007; 26: 411-9.

52. Van Assche G., D’Haens G., Noman M., Vermeire S., Hiele M., Asnong K. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. - 2003; 125: 1025-31.

53. Sjoberg M., Walch A., Meshkat M., Gustavsson A., Jarnerot G., Vogelsang H. et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm. Bowel Dis. - 2012; 18 (2), p. 212-8.

54. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L. et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. - 2010; 59: 1363-8.

55. Reinisch W., Sandborn W.J., Rutgeerts P., Feagan B.G., Rachmilewitz D., Hanauer S.B. et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm. Bowel Dis. - 2012; 18: 201-11.

56. Chebli L.A., LDdM Chaves, Pimentel F.F., Guerra D.M., RMdF Barros, Gaburri P.D. et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis. -2010; 16: 613-9.

57. Randall J.S.B., Warren B.F., Travis S.P., Mortensen N.J., George B.D. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br. J. Surg. - 2010; 97: 404-9.

58. Lennard-Jones J.E., Ritchie J.K., Hilder W., Spicer C.C. Assessment of severity in colitis: a preliminary study. Gut. - 1975; 16: 579-84.

59. Travis S.P., Farrant J.M., Ricketts C., Nolan D.J., Mortensen N.M., Kettlewell M.G. et al. Predicting outcome in severe ulcerative colitis. Gut. - 1996; 38: 905-10.

60. Lindgren S.C., Flood L.M., Kilander A.F., Lofberg R., Persson T.B., Sjodahl R.I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur. J. Gastroenterol.Hepatol. - 1998; 10: 831-5.

61. Benazzato L., D’Inca R., Grigoletto F., Perissinotto E., Medici V., Angriman I. et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig. Liver Dis. - 2004; 36: 461-6.

62. Almer S., Bodemar G., Franzen L., Lindstrom E., Nystrom P., Strom M. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet. - 1996; 347: 1731-5.

63. Carbonnel F., Lavergne A., Lemann M., Bitoun A., Valleur P., Hautefeuille P. et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig. Dis. Sci. - 1994; 39: 1550-7.

64. Ferrante M., Vermeire S., Katsanos K.H. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. - 2007 Feb; 13 (2): 123-8.

65. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology. - 2008 Sep-Oct; 55 (86-87): 1609-14.

66. Fasanmade A.A., Adedokun O.J., Olson A., Strauss R., Davis H.M. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int. J. Clin.Pharmacol.Ther. - 2010 May; 48 (5): 297-308.

67. Oussalah A., Evesque L., Laharie D., Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am. J. Gastroenterol. - 2010 Dec; 105 (12): 2617-25.

68. Головенко А.О., Халиф И.Л., Головенко О.В., Веселов В.В. Предикторы эффективности инфликсимаба у больных с тяжелой атакой язвенного колита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2013. - №3. -с. 65-73.

69. Cacheux W., Seksik P., Lemann M. et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am. J. Gastroenterol. - 2008. - Mar; 103 (3): 637-42.

70. Monterubbianesi R., Aratari A., Armuzzi A. et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J. Crohns Colitis. - 2014 Aug; 8 (8): 852-8.

71. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi P.G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. - 2006; 55: 47-53.

72. Panaccione R., Ghosh S., Middleton S. et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J. Crohns Colitis. - 2011; 5: 13.

73. Van Assche G., D’Haens G., Noman M., Vermeire S., Hiele M., Asnong K. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. - 2003; 125: 1025-31.

74. Van Assche G., D’Haens G., Noman M., Vermeire S., Hiele M., Asnong K. et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. - 2003; 125: 1025-31.

75. Gan S.I., Beck P.L. Anew look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am. J. Gastroenterol. - 2003; 98: 2363-2371.

76. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut. - 2001; 48: 526-35.

77. Jess T., Loftus Jr E.V., Velayos F.S. Harmsen W.S., Zinsmeister A.R., Smyrk T.C. et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. - 2006; 130: 1039-46.

78. Bergeron V., Vienne A., Sokol H., Seksik P., Nion-Larmurier I., Ruskone-Fourmestraux A. et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am. J. Gastroenterol. - 2010, [advance online publication, 15 June 2010].

79. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. - 2004; 126: 451-9.

80. Справочник по колопроктологии под редакцией проф. Шелыгина Ю.А., проф. Благодарного Л.А. «Литтерра». - 2012. - с. 460-522.

81. Travis S.P.L., Farrant J.M., Ricketts C. et al. Predicting outcome in severe ulcerative colitis. Gut. -1996; 38: 905-10.

82. Richards D.M., Hughes S.A., Irving M.H., Scott N.A. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis. - 2001; 3: 223-6.

83. McLaughlin S.D., Clark S.K., Thomas-Gibson S., Tekkis P., Ciclitira P.J., Nicholls R.J. Guide to endoscopy of the ileo-anal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis. - 2009; 15: 1256-63.

84. Berndtsson I., Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis - a prospective study. Colorectal Dis. - 2003; 5: 173-9.

85. Marcello P.W., Roberts P.L., Schoetz Jr D.J.,Coller J.A., Murray J.J., Veidenheimer M.C. Longterm results of the ileoanal pouch procedure. Arch. Surg. - 1993; 128: 500-3 [discussion 503-4].

86. Sagar P.M., Pemberton J.H. Ileo-anal pouch function and dysfunction. Dig. Dis. - 1997; 15: 17288.

87. Meagher A.P., Farouk R., Dozois R.R., Kelly K.A., Pemberton J.H. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and longterm outcome in 1310 patients. Br. J. Surg. - 1998; 85: 800-3.

88. Setti-Carraro P., Ritchie J.K., Wilkinson K.H. et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut. - 1994; 35: 1070-1075.

89. Fazio V.W., Ziv Y., Church J.M. et al. Ileal pouchanal anastomoses complications and function in 1005 patients. Ann. Surg. - 1995; 222: 120-127.

90. Belliveau P., Trudel J., Vasilevsky C.A. et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can. J. Surg. - 1999; 42: 345-352.

91. Pinto R.A., Canedo J., Murad-Regadas S., Regadas S.F., Weiss E.G., Wexner S.D. Ileal pouchanal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal. Dis. - 2011; 13: 177-83.

92. Church J.M. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust. N Z J. Surg. -2000; 70: 906-7.

93. Chapman J.R., Larson D.W., Wolff B.G., Dozois E.J., Cima R.R., Pemberton J.H. et al. Ileal pouch-anal anastomosis: does age at the timeof surgery affect outcome? Arch. Surg. - 2005; 140: 534-40.

94. Delaney C.P., Dadvand B., Remzi F.H., Church J.M., Fazio V.W. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis. Colon Rectum. - 2002; 45: 890-4.

95. Olsen K.O., Joelsson M., Laurberg S., Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br. J. Surg. - 1999; 86: 493-5.

96. Ording O.K., Juul S., Berndtsson I., Oresland T., Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. - 2002; 122: 15-9.

97. Gorgun E., Remzi F.H., Goldberg J.M., Thornton J., Bast J., Hull T.L. et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery. - 2004; 136: 795-803.

98. Johnson P., Richard C., Ravid A., Spencer L., Pinto E., Hanna M. et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis.Colon Rectum. - 2004; 47: 1119-26.

99. Oresland T., Palmblad S., Ellstrom M., Berndtsson I., Crona N., Hulten L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int. J. Colorectal. Dis. - 1994; 9: 77-81.

100. Alves A., Panis Y., Bouhnik Y., Maylin V., Lavergne-Slove A., Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J. Am. Coll Surg. - 2003; 197: 379-85.

101. Berg D.F., Bahadur singh A.M., Kaminski D.L., Longo W.E. Acute surgical emergencies in inflammatory bowel disease. Am. J. Surg. - 2002; 184: 45-51.

102. Hyman N.H., Cataldo P., Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis. Colon Rectum. - 2005; 48: 70-3.

103. Holubar S.D., Larson D.W., Dozois E.J., Pattana-Arun J., Pemberton J.H., Cima R.R. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis. Colon Rectum. - 2009; 52: 187-92.

104. Marceau C., Alves A., Ouaissi M., Bouhnik Y., Valleur P., Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery. - 2007; 141: 640.

105. Annibali R., Oresland T., Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis. Colon Rectum. - 1994; 37: 321-9.

106. Burns E.M., Bottle A., Aylin P., Clark S.K., Tekkis P., Darzi A. et al. Volume analysis of outcome following restorative proctocolectomy. Br. J. Surg. -2011; 98: 408-17.

107. Tekkis P.P., Fazio V.W., Lavery I.C., Remzi F.H., Senagore A.J., Wu J.S. et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann. Surg. - 2005; 241: 262-8.

108. Lepisto A. et al. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand. J. Surg. - 2005; 94: 40-2.

109. Burns E.M., Bottle A., Aylin P., Clark S.K., Tekkis P., Darzi A. et al. Volume analysis of outcome following restorative proctocolectomy. Br. J. Surg. -2011; 98: 408-17.

110. Burns E.M., Bottle A., Aylin P., Clark S.K., Tekkis P., Darzi A. et al. Volume analysis of outcome following restorative proctocolectomy. Br. J. Surg. -2011; 98: 408-17.

111. Edwards C.M., George B., Warren B.F. Diversion colitis: new light through old windows. Histopathology. - 1999. 35 (1): p. 86-7.

112. Annibali R., Oresland T., Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis. Colon Rectum. - 1994; 37: 321-9.

113. Shepherd N.A., Jass J.R., Duval I., Moskowitz R.L., Nicholls R.J., Morson B.C. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J. Clin.Pathol. - 1987; 40: 601-7.

114. SettiCarraro P.G., Talbot I.C., Nicholls J.R. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int. J. Colorectal. Dis. - 1998; 13: 103-7.

115. Ferrante M., D’Hoore A., Vermeire S. et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm. Bowel Dis. - 2009; 15: 1062-70.

116. Lake J.P., Firoozmand E., Kang J.C., Vassiliu P., Chan L.S., Vukasin P. et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J. Gastrointest. Surg. - 2004; 8: 547-51.

117. Mahadevan U., Loftus Jr E.V., Tremaine W.J., Pemberton J.H., Harmsen W.S., Schleck C.D. et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm. Bowel Dis. -2002; 8: 311-6.

118. Pugliese D., Armuzzi A., Rizzo G. et al. Effect of anti-TNF-alpha treatment on short-term postoperative complications in patients with inflammatory bowel disease. Gut. - 2010; 59 (Suppl III):A13.

119. SubramanianV., Pollok R.C., KangJ.Y., Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br. J. Surg. - 2006; 93: 793-9.

120. Yang Z., Wu Q., Wang F., Wu K., Fan D. Aliment PharmacolTher. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. - 2012 Nov; 36 (10): 922-8. doi: 10.1111/ apt.12060. Epub 2012 Sep 24.

121. Dignass A. et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns Colitis. - 2012. 6 (10): p. 991-1030.

122. Meagher A.P., Farouk R., Dozois R.R., Kelly K.A., Pemberton J.H. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and longterm outcome in 1310 patients. Br. J. Surg. - 1998; 85: 800-3.

123. Simchuk E.J., Thirlby R.C. Risk factors and true incidence of pouchitis in patients after ileal pouchanal anastomoses. World J. Surg. - 2000; 24: 851-6.

124. Stahlberg D., Gullberg K., Liljeqvist L., Hellers G., Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis. Colon Rectum. - 1996; 39: 1012-8.

125. Penna C., Tiret E., Kartheuser A., Hannoun L., Nordlinger B., Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br. J. Surg. - 1993; 80: 765-7.

126. Tjandra J.J., Fazio V.W., Church J.M., Oakley J.R., Milsom J.W., Lavery I.C. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am. J. Surg. - 1993; 165: 322-5.

127. Shen B., Achkar J.P., Lashner B.A. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am. J. Gastroenterol. - 2002 Apr; 97 (4): 972-7.

128. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am. J. Respir.Crit. Care Med. - 2005. 172 (9): p. 1169-227.

129. OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ ocebm-levels-of-evidence.


Для цитирования:


Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Ачкасов С.И., Барановский А.Ю., Болихов К.В., Валуйских Е.Ю., Варданян А.В., Веселов А.В., Веселов В.В., Головенко А.О., Головенко О.В., Григорьев Е.Г., Губонина И.В., Жигалова Т.Н., Кашников В.Н., Кизова Е.А., Князев О.В., Костенко Н.В., Куляпин А.В., Морозова Н.А., Муравьев А.В., Низов А.А., Никитина Н.В., Николаева Н.Н., Никулина Н.В., Одинцова А.Х., Осипенко М.Ф., Павленко В.В., Парфенов А.И., Полуэктова Е.А., Потапов А.С., Румянцев В.Г., Светлова И.О., Ситкин С.И., Тимербулатов В.М., Ткачев А.В., Ткаченко Е.И., Фролов С.А., Хубезов Д.А., Чашкова Е.Ю., Шапина М.В., Щукина О.Б., Яковлев А.А. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ РОССИЙСКОЙ ГАСТРОЭНТЕРОЛОГИЧЕСКОЙ АССОЦИАЦИИ И АССОЦИАЦИИ КОЛОПРОКТОЛОГОВ РОССИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ЯЗВЕННОГО КОЛИТА. Колопроктология. 2017;(1):6-30.

For citation:


., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., . CLINICAL GUIDE OF RUSSIAN ASSOCIATION OF GASTROENTEROLOGY AND RUSSIAN ASSOCIATION OF COLOPROCTOLOGY ON DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologia. 2017;(1):6-30. (In Russ.)

Просмотров: 151


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)